MX2015014904A - Reduccion del tamaño de particula de un compuesto antimuscarinico. - Google Patents

Reduccion del tamaño de particula de un compuesto antimuscarinico.

Info

Publication number
MX2015014904A
MX2015014904A MX2015014904A MX2015014904A MX2015014904A MX 2015014904 A MX2015014904 A MX 2015014904A MX 2015014904 A MX2015014904 A MX 2015014904A MX 2015014904 A MX2015014904 A MX 2015014904A MX 2015014904 A MX2015014904 A MX 2015014904A
Authority
MX
Mexico
Prior art keywords
particle size
size reduction
drug
antimuscarinic compound
antimuscarinic
Prior art date
Application number
MX2015014904A
Other languages
English (en)
Other versions
MX365295B (es
Inventor
Irene Pasquali
Andrea Casazza
Mark Saunders
Elena Losi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MX2015014904A publication Critical patent/MX2015014904A/es
Publication of MX365295B publication Critical patent/MX365295B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un proceso para preparar a particulado cristalino micronizado de una sal de glicopirronio. El proceso incluye suspender al fármaco en un antisolvente inmiscible en agua, en el cual el fármaco tiene poca o ninguna solubilidad y micronizar la suspensión. Las partículas de fármaco que se obtienen como resultado son físicamente estables con respecto a la aglomeración y/o agregación durante el almacenamiento.
MX2015014904A 2013-04-26 2014-04-24 Reduccion del tamaño de particula de un compuesto antimuscarinico. MX365295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165483 2013-04-26
PCT/EP2014/058295 WO2014173987A1 (en) 2013-04-26 2014-04-24 Particle size reduction of an antimuscarinic compound

Publications (2)

Publication Number Publication Date
MX2015014904A true MX2015014904A (es) 2016-03-07
MX365295B MX365295B (es) 2019-05-29

Family

ID=48190260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014904A MX365295B (es) 2013-04-26 2014-04-24 Reduccion del tamaño de particula de un compuesto antimuscarinico.

Country Status (28)

Country Link
US (2) US9393202B2 (es)
EP (2) EP2988728B1 (es)
JP (1) JP6449246B2 (es)
KR (1) KR102198354B1 (es)
CN (1) CN105120841B (es)
AR (1) AR096087A1 (es)
AU (1) AU2014259443B2 (es)
BR (1) BR112015024626B1 (es)
CA (1) CA2910314C (es)
DK (2) DK2988728T3 (es)
ES (2) ES2943109T3 (es)
FI (1) FI3574895T3 (es)
HK (1) HK1216302A1 (es)
HR (2) HRP20230337T1 (es)
HU (2) HUE062002T2 (es)
IL (1) IL242209A (es)
MX (1) MX365295B (es)
MY (1) MY169127A (es)
PH (1) PH12015502449A1 (es)
PL (2) PL2988728T3 (es)
PT (2) PT3574895T (es)
RU (1) RU2667636C2 (es)
SG (1) SG11201508760VA (es)
SI (2) SI3574895T1 (es)
TW (1) TWI630926B (es)
UA (1) UA120418C2 (es)
WO (1) WO2014173987A1 (es)
ZA (1) ZA201507916B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
SI3019153T1 (sl) 2013-07-11 2018-12-31 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
JP6653323B2 (ja) 2014-10-16 2020-02-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 吸入可能な製剤
JP6500522B2 (ja) * 2015-03-16 2019-04-17 セイコーエプソン株式会社 回路装置、物理量検出装置、電子機器及び移動体
DK3689379T3 (da) 2015-11-16 2021-09-06 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
LT3377108T (lt) 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Inhaliacinių miltelių kompozicijos, apimančios anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, paruošimo būdas
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
PT3490533T (pt) * 2016-07-29 2020-07-21 Inke Sa Processo de estabilização do tamanho de partícula

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0644755T3 (da) * 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CN1713893A (zh) * 2002-11-18 2005-12-28 纳幕尔杜邦公司 采用非球形研磨介质的介质研磨
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
ES2460576T3 (es) * 2007-12-13 2014-05-13 Novartis Ag Procedimiento para preparar una sustancia farmacológica en partículas y cristalina
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
DE102008000482A1 (de) 2008-03-03 2009-09-10 Zf Friedrichshafen Ag Ölgekühltes Reibschaltelement
BRPI0915803A2 (pt) * 2008-07-18 2015-11-10 Prosonix Ltd processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador
LT2435025T (lt) * 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
US20150093440A1 (en) * 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound

Also Published As

Publication number Publication date
US20140322142A1 (en) 2014-10-30
JP6449246B2 (ja) 2019-01-09
SG11201508760VA (en) 2015-11-27
UA120418C2 (uk) 2019-12-10
ZA201507916B (en) 2017-05-31
US9889094B2 (en) 2018-02-13
MY169127A (en) 2019-02-18
CA2910314C (en) 2022-03-01
PL2988728T3 (pl) 2020-02-28
US20160279066A1 (en) 2016-09-29
PL3574895T3 (pl) 2023-06-19
RU2667636C2 (ru) 2018-09-21
IL242209A (en) 2017-12-31
PT2988728T (pt) 2019-11-18
HUE062002T2 (hu) 2023-09-28
PH12015502449B1 (en) 2016-02-22
PH12015502449A1 (en) 2016-02-22
DK3574895T3 (da) 2023-05-01
KR20160002733A (ko) 2016-01-08
TWI630926B (zh) 2018-08-01
TW201521790A (zh) 2015-06-16
HRP20191882T1 (hr) 2019-12-27
HK1216302A1 (zh) 2016-11-04
FI3574895T3 (fi) 2023-05-25
EP2988728A1 (en) 2016-03-02
WO2014173987A1 (en) 2014-10-30
PT3574895T (pt) 2023-04-28
ES2754255T3 (es) 2020-04-16
EP2988728B1 (en) 2019-08-21
CN105120841A (zh) 2015-12-02
CA2910314A1 (en) 2014-10-30
AU2014259443B2 (en) 2019-01-03
EP3574895A1 (en) 2019-12-04
MX365295B (es) 2019-05-29
SI2988728T1 (sl) 2019-11-29
ES2943109T3 (es) 2023-06-09
CN105120841B (zh) 2019-04-30
RU2015145521A (ru) 2017-05-16
HUE046213T2 (hu) 2020-02-28
US9393202B2 (en) 2016-07-19
HRP20230337T1 (hr) 2023-06-09
AR096087A1 (es) 2015-12-02
AU2014259443A1 (en) 2015-11-12
BR112015024626B1 (pt) 2022-11-01
KR102198354B1 (ko) 2021-01-06
JP2016521274A (ja) 2016-07-21
DK2988728T3 (da) 2019-11-04
EP3574895B1 (en) 2023-03-22
SI3574895T1 (sl) 2023-05-31
BR112015024626A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
PH12015502449A1 (en) Particle size reduction of an antimuscarinic compound
HK1211579A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of athepsin 2--[221]-3-(--)-
HK1216173A1 (zh) -芳基取代的和 -雜芳基取代的 -羥基吡啶- -基-羰基氨基-鏈烷酸及其衍生物和其鹽,以及用相應 -羥基吡啶甲酸的衍生物進行製備的方法
HK1212616A1 (zh) 多孔載體顆粒和微粒化藥物的可吸入團聚物
HRP20221047T1 (hr) Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
SI2612851T1 (sl) Postopek za pripravo L-argininske soli perindoprila
HK1220444A1 (zh) 拉喹莫德鈉晶體和用於製造它們的改進方法
GB201813024D0 (en) System and methods for aggregation of cloud storage
EP2964032A4 (en) COMPOSITIONS AND METHOD FOR THE PRODUCTION OF VIRUSELIC PARTICLES
HK1187061A1 (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it
MX2015016958A (es) Sintesis de dicarbamatos de isohexida y derivados de estos.
GB201322840D0 (en) Aqueous suspension of inorganic particulate material
PL3083557T3 (pl) Sposób otrzymywania 3-podstawionych estrów kwasu (indol-1-ilo)-octowego
MX2018013764A (es) Cristal de derivado de quinolina.
HK1205449A1 (en) Package for solid preparation including 5-hydroxy-1h-imidazole-4- carboxamide or salt or hydrate thereof 5--1h--4-
PT3066076T (pt) Processo de preparação de metilfenidato de metilo e dos respetivos sais farmacêuticos
MX2018008824A (es) Preparacion de particulas micronizadas de un compuesto antimuscarinico por cavitacion hidrodinamica.
TH163807A (th) การลดขนาดอนุภาคของสารประกอบต้านมัสคารีน
TH163807B (th) การลดขนาดอนุภาคของสารประกอบต้านมัสคารีน
IN2014MU00328A (es)
GR1007770B (el) Φαρμακευτικο σκευασμα περιεχον ρεπαγλινιδη και μεθοδος για την παρασκευη αυτου
RU2014144841A (ru) Способ эндотелиопротекции наноструктурированным L-аргинином

Legal Events

Date Code Title Description
FG Grant or registration